JP2010533158A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010533158A5 JP2010533158A5 JP2010515600A JP2010515600A JP2010533158A5 JP 2010533158 A5 JP2010533158 A5 JP 2010533158A5 JP 2010515600 A JP2010515600 A JP 2010515600A JP 2010515600 A JP2010515600 A JP 2010515600A JP 2010533158 A5 JP2010533158 A5 JP 2010533158A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- phenyl
- pyrimidin
- cyclopropyl
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 nitro, hydroxy Chemical group 0.000 claims 119
- 125000000217 alkyl group Chemical group 0.000 claims 80
- 125000003545 alkoxy group Chemical group 0.000 claims 43
- 150000001875 compounds Chemical class 0.000 claims 31
- 125000005843 halogen group Chemical group 0.000 claims 25
- 229910052739 hydrogen Inorganic materials 0.000 claims 24
- 239000001257 hydrogen Substances 0.000 claims 24
- 150000003839 salts Chemical class 0.000 claims 23
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 22
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 19
- 125000004093 cyano group Chemical group *C#N 0.000 claims 17
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 14
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 14
- 125000001424 substituent group Chemical group 0.000 claims 11
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 claims 10
- 125000004432 carbon atom Chemical group C* 0.000 claims 10
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 10
- 150000002431 hydrogen Chemical class 0.000 claims 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 10
- 241001465754 Metazoa Species 0.000 claims 9
- 229910052799 carbon Inorganic materials 0.000 claims 9
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 8
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 7
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 7
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 7
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 claims 6
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 claims 6
- 125000004845 (C1-C6) alkylsulfonylamino group Chemical group 0.000 claims 5
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 5
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 5
- 125000005236 alkanoylamino group Chemical group 0.000 claims 5
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims 5
- 125000005153 alkyl sulfamoyl group Chemical group 0.000 claims 5
- 125000001589 carboacyl group Chemical group 0.000 claims 5
- 125000004452 carbocyclyl group Chemical group 0.000 claims 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 5
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 5
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 4
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 4
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 125000005936 piperidyl group Chemical group 0.000 claims 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 4
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 4
- 125000004516 1,2,4-thiadiazol-5-yl group Chemical group S1N=CN=C1* 0.000 claims 3
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 3
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 3
- 230000001028 anti-proliverative effect Effects 0.000 claims 3
- 239000004202 carbamide Substances 0.000 claims 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 3
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 3
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 3
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 2
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims 2
- 125000004463 2,4-dimethyl-thiazol-5-yl group Chemical group CC=1SC(=C(N1)C)* 0.000 claims 2
- 125000000972 4,5-dimethylthiazol-2-yl group Chemical group [H]C([H])([H])C1=C(N=C(*)S1)C([H])([H])[H] 0.000 claims 2
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 claims 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 2
- ODQJQEROUCVZNG-UHFFFAOYSA-N 5-fluoropyridine Chemical compound FC1=C=NC=C[CH]1 ODQJQEROUCVZNG-UHFFFAOYSA-N 0.000 claims 2
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 2
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims 2
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 claims 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 125000006299 oxetan-3-yl group Chemical group [H]C1([H])OC([H])([H])C1([H])* 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- JGBNGNTWBQKUHG-KRWDZBQOSA-N 1-(2-fluoroethyl)-3-[4-[4-[(3s)-3-methylmorpholin-4-yl]-6-[1-[(4-methyl-1,3-thiazol-2-yl)sulfonyl]cyclopropyl]pyrimidin-2-yl]phenyl]urea Chemical compound C[C@H]1COCCN1C1=CC(C2(CC2)S(=O)(=O)C=2SC=C(C)N=2)=NC(C=2C=CC(NC(=O)NCCF)=CC=2)=N1 JGBNGNTWBQKUHG-KRWDZBQOSA-N 0.000 claims 1
- PHWFBNWMJNYDGW-HNNXBMFYSA-N 1-(2-hydroxyethyl)-3-[4-[4-[(3s)-3-methylmorpholin-4-yl]-6-(1-methylsulfonylcyclopropyl)pyrimidin-2-yl]phenyl]thiourea Chemical compound C[C@H]1COCCN1C1=CC(C2(CC2)S(C)(=O)=O)=NC(C=2C=CC(NC(=S)NCCO)=CC=2)=N1 PHWFBNWMJNYDGW-HNNXBMFYSA-N 0.000 claims 1
- SDARAZUEIRWPTB-SFHVURJKSA-N 1-(2-hydroxyethyl)-3-[4-[4-[(3s)-3-methylmorpholin-4-yl]-6-(1-pyridin-2-ylsulfonylcyclopropyl)pyrimidin-2-yl]phenyl]urea Chemical compound C[C@H]1COCCN1C1=CC(C2(CC2)S(=O)(=O)C=2N=CC=CC=2)=NC(C=2C=CC(NC(=O)NCCO)=CC=2)=N1 SDARAZUEIRWPTB-SFHVURJKSA-N 0.000 claims 1
- GWHGRDMKYYLJQZ-SFHVURJKSA-N 1-(2-hydroxyethyl)-3-[4-[4-[(3s)-3-methylmorpholin-4-yl]-6-(1-pyridin-4-ylsulfonylcyclopropyl)pyrimidin-2-yl]phenyl]thiourea Chemical compound C[C@H]1COCCN1C1=CC(C2(CC2)S(=O)(=O)C=2C=CN=CC=2)=NC(C=2C=CC(NC(=S)NCCO)=CC=2)=N1 GWHGRDMKYYLJQZ-SFHVURJKSA-N 0.000 claims 1
- VWJHPGOSWDXNQV-KRWDZBQOSA-N 1-(2-hydroxyethyl)-3-[4-[4-[(3s)-3-methylmorpholin-4-yl]-6-[1-(1,3-thiazol-2-ylsulfonyl)cyclobutyl]pyrimidin-2-yl]phenyl]urea Chemical compound C[C@H]1COCCN1C1=CC(C2(CCC2)S(=O)(=O)C=2SC=CN=2)=NC(C=2C=CC(NC(=O)NCCO)=CC=2)=N1 VWJHPGOSWDXNQV-KRWDZBQOSA-N 0.000 claims 1
- QZAUFLOIQNLBCO-SFHVURJKSA-N 1-(2-hydroxyethyl)-3-[4-[4-[(3s)-3-methylmorpholin-4-yl]-6-[1-[(4-methyl-1,3-thiazol-2-yl)sulfonyl]cyclobutyl]pyrimidin-2-yl]phenyl]urea Chemical compound C[C@H]1COCCN1C1=CC(C2(CCC2)S(=O)(=O)C=2SC=C(C)N=2)=NC(C=2C=CC(NC(=O)NCCO)=CC=2)=N1 QZAUFLOIQNLBCO-SFHVURJKSA-N 0.000 claims 1
- RWHWLGUIESKCSW-KRWDZBQOSA-N 1-(2-hydroxyethyl)-3-[4-[4-[(3s)-3-methylmorpholin-4-yl]-6-[1-[(4-methyl-1,3-thiazol-2-yl)sulfonyl]cyclopropyl]pyrimidin-2-yl]phenyl]urea Chemical compound C[C@H]1COCCN1C1=CC(C2(CC2)S(=O)(=O)C=2SC=C(C)N=2)=NC(C=2C=CC(NC(=O)NCCO)=CC=2)=N1 RWHWLGUIESKCSW-KRWDZBQOSA-N 0.000 claims 1
- ZEIPTVRCOPZNMB-ROUUACIJSA-N 1-[(2s)-1-hydroxypropan-2-yl]-3-[4-[4-[(3s)-3-methylmorpholin-4-yl]-6-[1-(1,3-thiazol-2-ylsulfonyl)cyclobutyl]pyrimidin-2-yl]phenyl]urea Chemical compound C1=CC(NC(=O)N[C@H](CO)C)=CC=C1C1=NC(N2[C@H](COCC2)C)=CC(C2(CCC2)S(=O)(=O)C=2SC=CN=2)=N1 ZEIPTVRCOPZNMB-ROUUACIJSA-N 0.000 claims 1
- IZOIHVJEIVFFJZ-KRWDZBQOSA-N 1-[4-[4-(1-cyclopropylsulfonylcyclobutyl)-6-[(3s)-3-methylmorpholin-4-yl]pyrimidin-2-yl]phenyl]-3-(2-hydroxyethyl)urea Chemical compound C[C@H]1COCCN1C1=CC(C2(CCC2)S(=O)(=O)C2CC2)=NC(C=2C=CC(NC(=O)NCCO)=CC=2)=N1 IZOIHVJEIVFFJZ-KRWDZBQOSA-N 0.000 claims 1
- WGDGAMUOADKOIM-ROUUACIJSA-N 1-[4-[4-(1-cyclopropylsulfonylcyclobutyl)-6-[(3s)-3-methylmorpholin-4-yl]pyrimidin-2-yl]phenyl]-3-[(2s)-1-hydroxypropan-2-yl]urea Chemical compound C1=CC(NC(=O)N[C@H](CO)C)=CC=C1C1=NC(N2[C@H](COCC2)C)=CC(C2(CCC2)S(=O)(=O)C2CC2)=N1 WGDGAMUOADKOIM-ROUUACIJSA-N 0.000 claims 1
- JWGVUDPAMQEIJU-INIZCTEOSA-N 1-[4-[4-(1-cyclopropylsulfonylcyclopropyl)-6-[(3s)-3-methylmorpholin-4-yl]pyrimidin-2-yl]phenyl]-3-(2-hydroxyethyl)thiourea Chemical compound C[C@H]1COCCN1C1=CC(C2(CC2)S(=O)(=O)C2CC2)=NC(C=2C=CC(NC(=S)NCCO)=CC=2)=N1 JWGVUDPAMQEIJU-INIZCTEOSA-N 0.000 claims 1
- IUFFUJSXZMPACZ-INIZCTEOSA-N 1-[4-[4-(1-cyclopropylsulfonylcyclopropyl)-6-[(3s)-3-methylmorpholin-4-yl]pyrimidin-2-yl]phenyl]-3-(2-hydroxyethyl)urea Chemical compound C[C@H]1COCCN1C1=CC(C2(CC2)S(=O)(=O)C2CC2)=NC(C=2C=CC(NC(=O)NCCO)=CC=2)=N1 IUFFUJSXZMPACZ-INIZCTEOSA-N 0.000 claims 1
- KCXPUAAWQBOQAV-IRXDYDNUSA-N 1-[4-[4-(1-cyclopropylsulfonylcyclopropyl)-6-[(3s,5s)-3,5-dimethylmorpholin-4-yl]pyrimidin-2-yl]phenyl]-3-(2-hydroxyethyl)urea Chemical compound C[C@H]1COC[C@H](C)N1C1=CC(C2(CC2)S(=O)(=O)C2CC2)=NC(C=2C=CC(NC(=O)NCCO)=CC=2)=N1 KCXPUAAWQBOQAV-IRXDYDNUSA-N 0.000 claims 1
- SKEKHHDRURKHGL-KRWDZBQOSA-N 1-[4-[4-(1-ethylsulfonylcyclobutyl)-6-[(3s)-3-methylmorpholin-4-yl]pyrimidin-2-yl]phenyl]-3-(2-hydroxyethyl)thiourea Chemical compound C=1C(N2[C@H](COCC2)C)=NC(C=2C=CC(NC(=S)NCCO)=CC=2)=NC=1C1(S(=O)(=O)CC)CCC1 SKEKHHDRURKHGL-KRWDZBQOSA-N 0.000 claims 1
- JIVMEOCATHYZDN-HNNXBMFYSA-N 1-[4-[4-(1-ethylsulfonylcyclopropyl)-6-[(3s)-3-methylmorpholin-4-yl]pyrimidin-2-yl]phenyl]-3-methylurea Chemical compound C=1C(N2[C@H](COCC2)C)=NC(C=2C=CC(NC(=O)NC)=CC=2)=NC=1C1(S(=O)(=O)CC)CC1 JIVMEOCATHYZDN-HNNXBMFYSA-N 0.000 claims 1
- GMGAAJUMFDRDDP-SFHVURJKSA-N 1-[4-[4-[(3s)-3-ethylmorpholin-4-yl]-6-(1-methylsulfonylcyclopropyl)pyrimidin-2-yl]phenyl]-3-(2-hydroxyethyl)urea Chemical compound CC[C@H]1COCCN1C1=CC(C2(CC2)S(C)(=O)=O)=NC(C=2C=CC(NC(=O)NCCO)=CC=2)=N1 GMGAAJUMFDRDDP-SFHVURJKSA-N 0.000 claims 1
- DISAHEAVJOYDCP-HOTGVXAUSA-N 1-[4-[4-[(3s,5s)-3,5-dimethylmorpholin-4-yl]-6-(1-methylsulfonylcyclopropyl)pyrimidin-2-yl]phenyl]-3-(2-fluoroethyl)urea Chemical compound C[C@H]1COC[C@H](C)N1C1=CC(C2(CC2)S(C)(=O)=O)=NC(C=2C=CC(NC(=O)NCCF)=CC=2)=N1 DISAHEAVJOYDCP-HOTGVXAUSA-N 0.000 claims 1
- JNYGNLVZELHTJV-HOTGVXAUSA-N 1-[4-[4-[(3s,5s)-3,5-dimethylmorpholin-4-yl]-6-(1-methylsulfonylcyclopropyl)pyrimidin-2-yl]phenyl]-3-(2-hydroxyethyl)urea Chemical compound C[C@H]1COC[C@H](C)N1C1=CC(C2(CC2)S(C)(=O)=O)=NC(C=2C=CC(NC(=O)NCCO)=CC=2)=N1 JNYGNLVZELHTJV-HOTGVXAUSA-N 0.000 claims 1
- DYHHRFXAFJVSNH-HOTGVXAUSA-N 1-[4-[4-[(3s,5s)-3,5-dimethylmorpholin-4-yl]-6-(1-methylsulfonylcyclopropyl)pyrimidin-2-yl]phenyl]-3-ethylurea Chemical compound C1=CC(NC(=O)NCC)=CC=C1C1=NC(N2[C@H](COC[C@@H]2C)C)=CC(C2(CC2)S(C)(=O)=O)=N1 DYHHRFXAFJVSNH-HOTGVXAUSA-N 0.000 claims 1
- DPZWLHXUFZVCQC-KRWDZBQOSA-N 1-[4-[4-[1-(2,4-difluorophenyl)sulfonylcyclopropyl]-6-[(3s)-3-methylmorpholin-4-yl]pyrimidin-2-yl]phenyl]-3-(2-hydroxyethyl)urea Chemical compound C[C@H]1COCCN1C1=CC(C2(CC2)S(=O)(=O)C=2C(=CC(F)=CC=2)F)=NC(C=2C=CC(NC(=O)NCCO)=CC=2)=N1 DPZWLHXUFZVCQC-KRWDZBQOSA-N 0.000 claims 1
- LASWPFYHJKQHII-KRWDZBQOSA-N 1-[4-[4-[1-(2,6-difluorophenyl)sulfonylcyclopropyl]-6-[(3s)-3-methylmorpholin-4-yl]pyrimidin-2-yl]phenyl]-3-(2-hydroxyethyl)urea Chemical compound C[C@H]1COCCN1C1=CC(C2(CC2)S(=O)(=O)C=2C(=CC=CC=2F)F)=NC(C=2C=CC(NC(=O)NCCO)=CC=2)=N1 LASWPFYHJKQHII-KRWDZBQOSA-N 0.000 claims 1
- BPOSHVUVPVGZFR-SFHVURJKSA-N 1-[4-[4-[1-(2-chlorophenyl)sulfonylcyclopropyl]-6-[(3s)-3-methylmorpholin-4-yl]pyrimidin-2-yl]phenyl]-3-(2-hydroxyethyl)urea Chemical compound C[C@H]1COCCN1C1=CC(C2(CC2)S(=O)(=O)C=2C(=CC=CC=2)Cl)=NC(C=2C=CC(NC(=O)NCCO)=CC=2)=N1 BPOSHVUVPVGZFR-SFHVURJKSA-N 0.000 claims 1
- LIAMMPWRLCODBB-SFHVURJKSA-N 1-[4-[4-[1-(3-fluorophenyl)sulfonylcyclopropyl]-6-[(3s)-3-methylmorpholin-4-yl]pyrimidin-2-yl]phenyl]-3-(2-hydroxyethyl)urea Chemical compound C[C@H]1COCCN1C1=CC(C2(CC2)S(=O)(=O)C=2C=C(F)C=CC=2)=NC(C=2C=CC(NC(=O)NCCO)=CC=2)=N1 LIAMMPWRLCODBB-SFHVURJKSA-N 0.000 claims 1
- TZHFWCJOMAEYCX-SFHVURJKSA-N 1-[4-[4-[1-(4-chlorophenyl)sulfonylcyclopropyl]-6-[(3s)-3-methylmorpholin-4-yl]pyrimidin-2-yl]phenyl]-3-(2-hydroxyethyl)urea Chemical compound C[C@H]1COCCN1C1=CC(C2(CC2)S(=O)(=O)C=2C=CC(Cl)=CC=2)=NC(C=2C=CC(NC(=O)NCCO)=CC=2)=N1 TZHFWCJOMAEYCX-SFHVURJKSA-N 0.000 claims 1
- SZYYCRZNFMZYIA-FQEVSTJZSA-N 1-[4-[4-[1-(benzenesulfonyl)cyclobutyl]-6-[(3s)-3-methylmorpholin-4-yl]pyrimidin-2-yl]phenyl]-3-(2-hydroxyethyl)urea Chemical compound C[C@H]1COCCN1C1=CC(C2(CCC2)S(=O)(=O)C=2C=CC=CC=2)=NC(C=2C=CC(NC(=O)NCCO)=CC=2)=N1 SZYYCRZNFMZYIA-FQEVSTJZSA-N 0.000 claims 1
- RCKHBHLOCFDMNC-RTWAWAEBSA-N 1-[4-[4-[1-(benzenesulfonyl)cyclobutyl]-6-[(3s)-3-methylmorpholin-4-yl]pyrimidin-2-yl]phenyl]-3-[(2r)-1-hydroxypropan-2-yl]urea Chemical compound C1=CC(NC(=O)N[C@@H](CO)C)=CC=C1C1=NC(N2[C@H](COCC2)C)=CC(C2(CCC2)S(=O)(=O)C=2C=CC=CC=2)=N1 RCKHBHLOCFDMNC-RTWAWAEBSA-N 0.000 claims 1
- RCKHBHLOCFDMNC-SFTDATJTSA-N 1-[4-[4-[1-(benzenesulfonyl)cyclobutyl]-6-[(3s)-3-methylmorpholin-4-yl]pyrimidin-2-yl]phenyl]-3-[(2s)-1-hydroxypropan-2-yl]urea Chemical compound C1=CC(NC(=O)N[C@H](CO)C)=CC=C1C1=NC(N2[C@H](COCC2)C)=CC(C2(CCC2)S(=O)(=O)C=2C=CC=CC=2)=N1 RCKHBHLOCFDMNC-SFTDATJTSA-N 0.000 claims 1
- ZBKXTIXUBBIJJH-QFIPXVFZSA-N 1-[4-[4-[1-(benzenesulfonyl)cyclopropyl]-6-[(3s)-3-ethylmorpholin-4-yl]pyrimidin-2-yl]phenyl]-3-(2-fluoroethyl)urea Chemical compound CC[C@H]1COCCN1C1=CC(C2(CC2)S(=O)(=O)C=2C=CC=CC=2)=NC(C=2C=CC(NC(=O)NCCF)=CC=2)=N1 ZBKXTIXUBBIJJH-QFIPXVFZSA-N 0.000 claims 1
- OFXOHIFHOGGYQA-QFIPXVFZSA-N 1-[4-[4-[1-(benzenesulfonyl)cyclopropyl]-6-[(3s)-3-ethylmorpholin-4-yl]pyrimidin-2-yl]phenyl]-3-(2-hydroxyethyl)urea Chemical compound CC[C@H]1COCCN1C1=CC(C2(CC2)S(=O)(=O)C=2C=CC=CC=2)=NC(C=2C=CC(NC(=O)NCCO)=CC=2)=N1 OFXOHIFHOGGYQA-QFIPXVFZSA-N 0.000 claims 1
- UKMGZCCESJGQDR-QHCPKHFHSA-N 1-[4-[4-[1-(benzenesulfonyl)cyclopropyl]-6-[(3s)-3-ethylmorpholin-4-yl]pyrimidin-2-yl]phenyl]-3-[(1-hydroxycyclopropyl)methyl]urea Chemical compound CC[C@H]1COCCN1C1=CC(C2(CC2)S(=O)(=O)C=2C=CC=CC=2)=NC(C=2C=CC(NC(=O)NCC3(O)CC3)=CC=2)=N1 UKMGZCCESJGQDR-QHCPKHFHSA-N 0.000 claims 1
- YSGRDNBPPYGZHE-REWPJTCUSA-N 1-[4-[4-[1-(benzenesulfonyl)cyclopropyl]-6-[(3s)-3-ethylmorpholin-4-yl]pyrimidin-2-yl]phenyl]-3-[(2s)-1-hydroxypropan-2-yl]urea Chemical compound CC[C@H]1COCCN1C1=CC(C2(CC2)S(=O)(=O)C=2C=CC=CC=2)=NC(C=2C=CC(NC(=O)N[C@@H](C)CO)=CC=2)=N1 YSGRDNBPPYGZHE-REWPJTCUSA-N 0.000 claims 1
- GVGXIFVNHJJNBU-QHCPKHFHSA-N 1-[4-[4-[1-(benzenesulfonyl)cyclopropyl]-6-[(3s)-3-ethylmorpholin-4-yl]pyrimidin-2-yl]phenyl]-3-cyclopropylurea Chemical compound CC[C@H]1COCCN1C1=CC(C2(CC2)S(=O)(=O)C=2C=CC=CC=2)=NC(C=2C=CC(NC(=O)NC3CC3)=CC=2)=N1 GVGXIFVNHJJNBU-QHCPKHFHSA-N 0.000 claims 1
- KINNLISVUQBYHB-NRFANRHFSA-N 1-[4-[4-[1-(benzenesulfonyl)cyclopropyl]-6-[(3s)-3-ethylmorpholin-4-yl]pyrimidin-2-yl]phenyl]-3-methylurea Chemical compound CC[C@H]1COCCN1C1=CC(C2(CC2)S(=O)(=O)C=2C=CC=CC=2)=NC(C=2C=CC(NC(=O)NC)=CC=2)=N1 KINNLISVUQBYHB-NRFANRHFSA-N 0.000 claims 1
- UDSPUWQOVJXCKB-FQEVSTJZSA-N 1-[4-[4-[1-(benzenesulfonyl)cyclopropyl]-6-[(3s)-3-methylmorpholin-4-yl]pyrimidin-2-yl]phenyl]-3-(1h-imidazol-2-ylmethyl)thiourea Chemical compound C[C@H]1COCCN1C1=CC(C2(CC2)S(=O)(=O)C=2C=CC=CC=2)=NC(C=2C=CC(NC(=S)NCC=3NC=CN=3)=CC=2)=N1 UDSPUWQOVJXCKB-FQEVSTJZSA-N 0.000 claims 1
- HRFPKXLTEQFONU-SFHVURJKSA-N 1-[4-[4-[1-(benzenesulfonyl)cyclopropyl]-6-[(3s)-3-methylmorpholin-4-yl]pyrimidin-2-yl]phenyl]-3-(2,2-difluoroethyl)urea Chemical compound C[C@H]1COCCN1C1=CC(C2(CC2)S(=O)(=O)C=2C=CC=CC=2)=NC(C=2C=CC(NC(=O)NCC(F)F)=CC=2)=N1 HRFPKXLTEQFONU-SFHVURJKSA-N 0.000 claims 1
- WDWITOKODXBSEY-IBGZPJMESA-N 1-[4-[4-[1-(benzenesulfonyl)cyclopropyl]-6-[(3s)-3-methylmorpholin-4-yl]pyrimidin-2-yl]phenyl]-3-(2-fluoroethyl)urea Chemical compound C[C@H]1COCCN1C1=CC(C2(CC2)S(=O)(=O)C=2C=CC=CC=2)=NC(C=2C=CC(NC(=O)NCCF)=CC=2)=N1 WDWITOKODXBSEY-IBGZPJMESA-N 0.000 claims 1
- SISSPCWSSLRIEP-IBGZPJMESA-N 1-[4-[4-[1-(benzenesulfonyl)cyclopropyl]-6-[(3s)-3-methylmorpholin-4-yl]pyrimidin-2-yl]phenyl]-3-(2-hydroxyethyl)urea Chemical compound C[C@H]1COCCN1C1=CC(C2(CC2)S(=O)(=O)C=2C=CC=CC=2)=NC(C=2C=CC(NC(=O)NCCO)=CC=2)=N1 SISSPCWSSLRIEP-IBGZPJMESA-N 0.000 claims 1
- QQUCRBWPHRAIHZ-FQEVSTJZSA-N 1-[4-[4-[1-(benzenesulfonyl)cyclopropyl]-6-[(3s)-3-methylmorpholin-4-yl]pyrimidin-2-yl]phenyl]-3-(3-hydroxypropyl)urea Chemical compound C[C@H]1COCCN1C1=CC(C2(CC2)S(=O)(=O)C=2C=CC=CC=2)=NC(C=2C=CC(NC(=O)NCCCO)=CC=2)=N1 QQUCRBWPHRAIHZ-FQEVSTJZSA-N 0.000 claims 1
- PNRNJYMCLCZTMG-UXHICEINSA-N 1-[4-[4-[1-(benzenesulfonyl)cyclopropyl]-6-[(3s)-3-methylmorpholin-4-yl]pyrimidin-2-yl]phenyl]-3-[(2r)-1-hydroxypropan-2-yl]urea Chemical compound C1=CC(NC(=O)N[C@@H](CO)C)=CC=C1C1=NC(N2[C@H](COCC2)C)=CC(C2(CC2)S(=O)(=O)C=2C=CC=CC=2)=N1 PNRNJYMCLCZTMG-UXHICEINSA-N 0.000 claims 1
- PNRNJYMCLCZTMG-PMACEKPBSA-N 1-[4-[4-[1-(benzenesulfonyl)cyclopropyl]-6-[(3s)-3-methylmorpholin-4-yl]pyrimidin-2-yl]phenyl]-3-[(2s)-1-hydroxypropan-2-yl]urea Chemical compound C1=CC(NC(=O)N[C@H](CO)C)=CC=C1C1=NC(N2[C@H](COCC2)C)=CC(C2(CC2)S(=O)(=O)C=2C=CC=CC=2)=N1 PNRNJYMCLCZTMG-PMACEKPBSA-N 0.000 claims 1
- MOOQAPDBCQJTET-IBGZPJMESA-N 1-[4-[4-[1-(benzenesulfonyl)cyclopropyl]-6-[(3s)-3-methylmorpholin-4-yl]pyrimidin-2-yl]phenyl]-3-cyclopropylurea Chemical compound C[C@H]1COCCN1C1=CC(C2(CC2)S(=O)(=O)C=2C=CC=CC=2)=NC(C=2C=CC(NC(=O)NC3CC3)=CC=2)=N1 MOOQAPDBCQJTET-IBGZPJMESA-N 0.000 claims 1
- ATXRDEYUAHGJHH-SFHVURJKSA-N 1-[4-[4-[1-(benzenesulfonyl)cyclopropyl]-6-[(3s)-3-methylmorpholin-4-yl]pyrimidin-2-yl]phenyl]-3-methylthiourea Chemical compound C1=CC(NC(=S)NC)=CC=C1C1=NC(N2[C@H](COCC2)C)=CC(C2(CC2)S(=O)(=O)C=2C=CC=CC=2)=N1 ATXRDEYUAHGJHH-SFHVURJKSA-N 0.000 claims 1
- PYENJMDTDGSGCV-PMACEKPBSA-N 1-[4-[4-[1-(benzenesulfonyl)cyclopropyl]-6-[(3s,5s)-3,5-dimethylmorpholin-4-yl]pyrimidin-2-yl]phenyl]-3-(2-fluoroethyl)urea Chemical compound C[C@H]1COC[C@H](C)N1C1=CC(C2(CC2)S(=O)(=O)C=2C=CC=CC=2)=NC(C=2C=CC(NC(=O)NCCF)=CC=2)=N1 PYENJMDTDGSGCV-PMACEKPBSA-N 0.000 claims 1
- LDSDKFOLECLJSQ-PMACEKPBSA-N 1-[4-[4-[1-(benzenesulfonyl)cyclopropyl]-6-[(3s,5s)-3,5-dimethylmorpholin-4-yl]pyrimidin-2-yl]phenyl]-3-(2-hydroxyethyl)urea Chemical compound C[C@H]1COC[C@H](C)N1C1=CC(C2(CC2)S(=O)(=O)C=2C=CC=CC=2)=NC(C=2C=CC(NC(=O)NCCO)=CC=2)=N1 LDSDKFOLECLJSQ-PMACEKPBSA-N 0.000 claims 1
- PADUHJGFBCCSJN-PMACEKPBSA-N 1-[4-[4-[1-(benzenesulfonyl)cyclopropyl]-6-[(3s,5s)-3,5-dimethylmorpholin-4-yl]pyrimidin-2-yl]phenyl]-3-cyclopropylurea Chemical compound C[C@H]1COC[C@H](C)N1C1=CC(C2(CC2)S(=O)(=O)C=2C=CC=CC=2)=NC(C=2C=CC(NC(=O)NC3CC3)=CC=2)=N1 PADUHJGFBCCSJN-PMACEKPBSA-N 0.000 claims 1
- MGMYHZZLGCHORC-OALUTQOASA-N 1-[4-[4-[1-(benzenesulfonyl)cyclopropyl]-6-[(3s,5s)-3,5-dimethylmorpholin-4-yl]pyrimidin-2-yl]phenyl]-3-methylurea Chemical compound C1=CC(NC(=O)NC)=CC=C1C1=NC(N2[C@H](COC[C@@H]2C)C)=CC(C2(CC2)S(=O)(=O)C=2C=CC=CC=2)=N1 MGMYHZZLGCHORC-OALUTQOASA-N 0.000 claims 1
- PRPJUVWIAAVHFQ-UHFFFAOYSA-N 1-cyclopropyl-3-[4-[4-(1-methylsulfonylcyclopropyl)-6-morpholin-4-ylpyrimidin-2-yl]phenyl]urea Chemical compound C=1C(N2CCOCC2)=NC(C=2C=CC(NC(=O)NC3CC3)=CC=2)=NC=1C1(S(=O)(=O)C)CC1 PRPJUVWIAAVHFQ-UHFFFAOYSA-N 0.000 claims 1
- KMAVNZVCOZUTRU-IBGZPJMESA-N 1-cyclopropyl-3-[4-[4-[(3s)-3-ethylmorpholin-4-yl]-6-(1-methylsulfonylcyclopropyl)pyrimidin-2-yl]phenyl]urea Chemical compound CC[C@H]1COCCN1C1=CC(C2(CC2)S(C)(=O)=O)=NC(C=2C=CC(NC(=O)NC3CC3)=CC=2)=N1 KMAVNZVCOZUTRU-IBGZPJMESA-N 0.000 claims 1
- VDACHYLQEIVCET-HOTGVXAUSA-N 1-cyclopropyl-3-[4-[4-[(3s,5s)-3,5-dimethylmorpholin-4-yl]-6-(1-methylsulfonylcyclopropyl)pyrimidin-2-yl]phenyl]urea Chemical compound C[C@H]1COC[C@H](C)N1C1=CC(C2(CC2)S(C)(=O)=O)=NC(C=2C=CC(NC(=O)NC3CC3)=CC=2)=N1 VDACHYLQEIVCET-HOTGVXAUSA-N 0.000 claims 1
- ZINIPRIVILXKJX-KRWDZBQOSA-N 1-cyclopropyl-3-[4-[4-[1-(3-hydroxypropylsulfonyl)cyclopropyl]-6-[(3s)-3-methylmorpholin-4-yl]pyrimidin-2-yl]phenyl]thiourea Chemical compound C[C@H]1COCCN1C1=CC(C2(CC2)S(=O)(=O)CCCO)=NC(C=2C=CC(NC(=S)NC3CC3)=CC=2)=N1 ZINIPRIVILXKJX-KRWDZBQOSA-N 0.000 claims 1
- VCXQPNHGNFCRGA-SFHVURJKSA-N 1-cyclopropyl-3-[4-[4-[1-(4-fluorophenyl)sulfonylcyclopropyl]-6-[(3s)-3-methylmorpholin-4-yl]pyrimidin-2-yl]phenyl]thiourea Chemical compound C[C@H]1COCCN1C1=CC(C2(CC2)S(=O)(=O)C=2C=CC(F)=CC=2)=NC(C=2C=CC(NC(=S)NC3CC3)=CC=2)=N1 VCXQPNHGNFCRGA-SFHVURJKSA-N 0.000 claims 1
- JYDYLIYPDHGUEZ-KRWDZBQOSA-N 1-ethyl-3-[4-[4-[1-(3-hydroxypropylsulfonyl)cyclopropyl]-6-[(3s)-3-methylmorpholin-4-yl]pyrimidin-2-yl]phenyl]thiourea Chemical compound C1=CC(NC(=S)NCC)=CC=C1C1=NC(N2[C@H](COCC2)C)=CC(C2(CC2)S(=O)(=O)CCCO)=N1 JYDYLIYPDHGUEZ-KRWDZBQOSA-N 0.000 claims 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 claims 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 claims 1
- 125000001054 5 membered carbocyclic group Chemical group 0.000 claims 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims 1
- ZUSWDTWYONAOPH-UHFFFAOYSA-N [2-(trifluoromethyl)phenyl]hydrazine;hydrochloride Chemical group [Cl-].[NH3+]NC1=CC=CC=C1C(F)(F)F ZUSWDTWYONAOPH-UHFFFAOYSA-N 0.000 claims 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- XUCNUKMRBVNAPB-UHFFFAOYSA-N fluoroethene Chemical group FC=C XUCNUKMRBVNAPB-UHFFFAOYSA-N 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000005302 thiazolylmethyl group Chemical group [H]C1=C([H])N=C(S1)C([H])([H])* 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 125000005301 thienylmethyl group Chemical group [H]C1=C([H])C([H])=C(S1)C([H])([H])* 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94856607P | 2007-07-09 | 2007-07-09 | |
| US3029708P | 2008-02-21 | 2008-02-21 | |
| PCT/GB2008/050546 WO2009007748A2 (en) | 2007-07-09 | 2008-07-08 | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010533158A JP2010533158A (ja) | 2010-10-21 |
| JP2010533158A5 true JP2010533158A5 (cg-RX-API-DMAC10.html) | 2012-08-30 |
Family
ID=40010883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010515600A Pending JP2010533158A (ja) | 2007-07-09 | 2008-07-08 | 化合物類−９４５ |
Country Status (20)
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX315904B (es) | 2008-05-30 | 2013-11-29 | Amgen Inc | Inhibidores de fosfoinosituro-3 cinasa. |
| TWI378933B (en) | 2008-10-14 | 2012-12-11 | Daiichi Sankyo Co Ltd | Morpholinopurine derivatives |
| UY32351A (es) | 2008-12-22 | 2010-07-30 | Astrazeneca Ab | Compuestos de pirimidinil indol para uso como inhibidores de atr |
| US8785457B2 (en) | 2009-03-13 | 2014-07-22 | Cellzome Limited | Pyrimidine derivatives as mTOR inhibitors |
| UY32582A (es) | 2009-04-28 | 2010-11-30 | Amgen Inc | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero |
| US8946204B2 (en) | 2009-05-07 | 2015-02-03 | Gruenenthal Gmbh | Substituted phenylureas and phenylamides as vanilloid receptor ligands |
| ES2640257T3 (es) | 2009-05-07 | 2017-11-02 | Medifron Dbt Inc. | Fenilureas y fenilamidas sustituidas como ligandos del receptor vanilloide |
| EA021088B1 (ru) | 2009-07-02 | 2015-04-30 | Санофи | Производные (6-оксо-1,6-дигидропиримидин-2-ил)амида, их получение и их фармацевтическое применение в качестве ингибиторов фосфорилирования akt (pkb) |
| EP2448932B1 (fr) | 2009-07-02 | 2014-03-05 | Sanofi | Nouveaux derives de 6-morpholin-4-yl-pyrimidin-4-(3h)-one, leur preparation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb) |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| PH12012500809A1 (en) | 2009-10-30 | 2012-11-26 | Ariad Pharma Inc | Methods and compositions for treating cancer |
| JP6114554B2 (ja) | 2010-02-03 | 2017-04-12 | シグナル ファーマシューティカルズ，エルエルシー | Ｔｏｒキナーゼ阻害剤に対する感受性についての予測的なバイオマーカーとしてのｌｋｂ１変異の同定 |
| WO2011107585A1 (en) | 2010-03-04 | 2011-09-09 | Cellzome Limited | Morpholino substituted urea derivatives as mtor inhibitors |
| IN2013MN00581A (cg-RX-API-DMAC10.html) * | 2010-09-03 | 2015-06-05 | Piramal Entpr Ltd | |
| US8440662B2 (en) | 2010-10-31 | 2013-05-14 | Endo Pharmaceuticals, Inc. | Substituted quinazoline and pyrido-pyrimidine derivatives |
| HUE030393T2 (en) | 2010-12-28 | 2017-05-29 | Sanofi Sa | New pyrimidine derivatives, a process for their preparation, and their pharmaceutical use as inhibitors of AKT (PKB) phosphorylation |
| JP2014510122A (ja) | 2011-04-04 | 2014-04-24 | セルゾーム リミテッド | ｍＴＯＲ阻害剤としてのジヒドロピロロピリミジン誘導体 |
| CA2843887A1 (en) | 2011-08-03 | 2013-02-07 | Signal Pharmaceuticals, Llc | Identification of gene expression profile as a predictive biomarker for lkb1 status |
| CA2849189A1 (en) | 2011-09-21 | 2013-03-28 | Cellzome Limited | Morpholino substituted urea or carbamate derivatives as mtor inhibitors |
| GEP20166432B (en) | 2011-09-27 | 2016-02-10 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
| CN103946222B (zh) | 2011-10-07 | 2016-12-28 | 塞尔佐姆有限公司 | 作为mtor抑制剂的吗啉代取代的双环嘧啶脲或氨基甲酸衍生物 |
| UY34632A (es) | 2012-02-24 | 2013-05-31 | Novartis Ag | Compuestos de oxazolidin- 2- ona y usos de los mismos |
| CN104350144B (zh) | 2012-05-23 | 2017-08-04 | 弗·哈夫曼-拉罗切有限公司 | 获得和使用内胚层和肝细胞的组合物和方法 |
| AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
| US9296733B2 (en) | 2012-11-12 | 2016-03-29 | Novartis Ag | Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases |
| WO2014141104A1 (en) | 2013-03-14 | 2014-09-18 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
| TWI631949B (zh) | 2013-04-17 | 2018-08-11 | 標誌製藥公司 | 使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法 |
| MX377267B (es) | 2013-04-17 | 2025-03-07 | Signal Pharm Llc | Tratamiento de cáncer con dihidropirazino-pirazinas. |
| CA2909629C (en) | 2013-04-17 | 2022-12-13 | Signal Pharmaceuticals, Llc | Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one |
| WO2014172436A1 (en) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer |
| TW201521725A (zh) | 2013-04-17 | 2015-06-16 | Signal Pharm Llc | 使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法 |
| SG10201708111YA (en) | 2013-04-17 | 2017-11-29 | Signal Pharm Llc | Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer |
| JP6382946B2 (ja) | 2013-04-17 | 2018-08-29 | シグナル ファーマシューティカルズ，エルエルシー | ジヒドロピラジノ−ピラジンによる癌治療 |
| CA3143529A1 (en) | 2013-05-29 | 2014-12-04 | Signal Pharmaceuticals, Llc | Pharmaceutical compositions 0f 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use |
| NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
| EP3131551A4 (en) | 2014-04-16 | 2017-09-20 | Signal Pharmaceuticals, LLC | SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF |
| CN106458921B (zh) | 2014-05-21 | 2020-03-24 | 阿勒根公司 | 作为甲酰肽受体调节剂的咪唑衍生物 |
| CA2957046C (en) | 2014-08-04 | 2022-11-15 | Nuevolution A/S | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases |
| LT3524595T (lt) | 2014-08-28 | 2022-09-26 | Eisai R&D Management Co., Ltd. | Aukšto grynumo chinolino darinys ir jo gamybos būdas |
| US10227324B2 (en) | 2014-12-17 | 2019-03-12 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | 2-morpholin-4,6-disubstituted pyrimidine derivative, and preparation method and pharmaceutical use thereof |
| US10202365B2 (en) | 2015-02-06 | 2019-02-12 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors |
| WO2017011776A1 (en) | 2015-07-16 | 2017-01-19 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
| EP3368039A1 (en) | 2015-10-26 | 2018-09-05 | The Regents of The University of Colorado, A Body Corporate | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| RS65069B1 (sr) | 2015-11-02 | 2024-02-29 | Blueprint Medicines Corp | Inhibitori ret-a |
| WO2017161269A1 (en) | 2016-03-17 | 2017-09-21 | Blueprint Medicines Corporation | Inhibitors of ret receptor tyrosine kinases |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| LT3439663T (lt) | 2016-04-04 | 2024-10-10 | Loxo Oncology, Inc. | Vaikų vėžio gydymo būdai |
| HUE068971T2 (hu) | 2016-04-04 | 2025-02-28 | Loxo Oncology Inc | (S)-N-(5-((R)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-A]pirimidin-3-il) -3-hidroxipirrolidin-1-karboxamid folyékony készítményei |
| PT3800189T (pt) | 2016-05-18 | 2023-07-27 | Array Biopharma Inc | Preparação de (s)-n-(5-((r)-2-(2,5- difluoropenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3- il)-3-hidroxipirrolidina-1-carboxamida |
| US10227329B2 (en) | 2016-07-22 | 2019-03-12 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| CN110267960B (zh) | 2017-01-18 | 2022-04-26 | 阿雷生物药品公司 | 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡嗪化合物 |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| EP3630116B1 (en) | 2017-05-26 | 2024-05-01 | The Board Of Regents Of The University Of Texas System | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase |
| BR112019027402A2 (pt) | 2017-06-22 | 2020-07-07 | Celgene Corporation | tratamento de carcinoma hepatocelular caracterizado por infecção pelo vírus da hepatite b |
| IL271930B (en) | 2017-07-13 | 2022-07-01 | Univ Texas | Heterocyclic inhibitors of atr kinase |
| US10800774B2 (en) | 2017-08-17 | 2020-10-13 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of ATR kinase |
| TWI876442B (zh) | 2017-10-10 | 2025-03-11 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| US11603374B2 (en) | 2018-01-18 | 2023-03-14 | Array Biopharma Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
| EP3740490A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors |
| CA3087972C (en) | 2018-01-18 | 2023-01-10 | Array Biopharma Inc. | Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors |
| CN112218631B (zh) | 2018-03-16 | 2023-12-22 | 德州大学系统董事会 | Atr激酶的杂环抑制剂 |
| ES2970041T3 (es) | 2018-04-03 | 2024-05-24 | Blueprint Medicines Corp | Inhibidor de RET para su uso en el tratamiento del cáncer que tiene una alteración de RET |
| WO2020028258A1 (en) | 2018-07-31 | 2020-02-06 | Loxo Oncology, Inc. | Spray-dried dispersions and formulations of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoro propan-2-yl)-1h-pyrazole-4-carboxamide |
| CN112996794A (zh) | 2018-09-10 | 2021-06-18 | 阿雷生物药品公司 | 作为ret激酶抑制剂的稠合杂环化合物 |
| US12180207B2 (en) | 2018-12-19 | 2024-12-31 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of FGFR tyrosine kinases |
| EP3898615A1 (en) | 2018-12-19 | 2021-10-27 | Array Biopharma, Inc. | 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer |
| EP4069369A4 (en) | 2019-12-06 | 2024-02-14 | Schrödinger, Inc. | CYCLIC COMPOUNDS AND METHODS OF USE THEREOF |
| US11685727B2 (en) | 2019-12-20 | 2023-06-27 | Nuevolution A/S | Compounds active towards nuclear receptors |
| WO2021124277A1 (en) | 2019-12-20 | 2021-06-24 | Nuevolution A/S | Compounds active towards nuclear receptors |
| US20240018157A1 (en) | 2019-12-27 | 2024-01-18 | Schrödinger, Inc. | Cyclic compounds and methods of using same |
| EP4126874A1 (en) | 2020-03-31 | 2023-02-08 | Nuevolution A/S | Compounds active towards nuclear receptors |
| AU2021249530A1 (en) | 2020-03-31 | 2022-12-01 | Nuevolution A/S | Compounds active towards nuclear receptors |
| BR112022024382A2 (pt) | 2020-05-29 | 2023-05-02 | Blueprint Medicines Corp | Formas sólidas de pralsetinibe |
| CN111646985A (zh) * | 2020-06-01 | 2020-09-11 | 江苏集萃分子工程研究院有限公司 | 一种含嘧啶杂环抗肿瘤药物分子azd6738的合成方法 |
| JP2023541047A (ja) | 2020-09-10 | 2023-09-27 | シュレーディンガー， インコーポレイテッド | がんの治療のための複素環式ペリ縮環ｃｄｃ７キナーゼ阻害剤 |
| EP4284804A1 (en) | 2021-01-26 | 2023-12-06 | Schrödinger, Inc. | Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disorders |
| TW202300150A (zh) | 2021-03-18 | 2023-01-01 | 美商薛定諤公司 | 環狀化合物及其使用方法 |
| CN118317943A (zh) * | 2021-12-02 | 2024-07-09 | 百济神州有限公司 | 手性3,5-二取代吗啉化合物的合成方法及其有用的中间体 |
| WO2025059027A1 (en) | 2023-09-11 | 2025-03-20 | Schrödinger, Inc. | Cyclopenta[e]pyrazolo[1,5-a]pyrimidine derivatives as malt1 inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3922735A1 (de) * | 1989-07-11 | 1991-01-24 | Hoechst Ag | Aminopyrimidin-derivate, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide |
| WO2002038551A1 (en) * | 2000-11-10 | 2002-05-16 | F. Hoffman-La Roche Ag | Pyrimidine derivatives and their use as neuropeptide y receptor ligands |
| WO2005094828A1 (en) * | 2004-03-02 | 2005-10-13 | F. Hoffmann-La Roche Ag | 4- (sulfanyl-pyrimidin-4-ylmethyl) -morpholine derivatives and related compounds as gaba receptor ligands for the treatment of anxiety, depression and epilepsy |
| US7772271B2 (en) * | 2004-07-14 | 2010-08-10 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| BRPI0615781A2 (pt) * | 2005-09-01 | 2009-06-16 | Array Biopharma Inc | compostos inibidores de raf e métodos de uso destes |
| GB0520657D0 (en) * | 2005-10-11 | 2005-11-16 | Ludwig Inst Cancer Res | Pharmaceutical compounds |
| KR101435231B1 (ko) * | 2006-08-24 | 2014-10-02 | 아스트라제네카 아베 | 증식성 질환의 치료에 유용한 모르폴리노 피리미딘 유도체 |
| CN101796048A (zh) * | 2007-07-09 | 2010-08-04 | 阿斯利康(瑞典)有限公司 | 用于治疗增殖病症的三取代的嘧啶衍生物 |
| US8138183B2 (en) * | 2007-07-09 | 2012-03-20 | Astrazeneca Ab | Morpholino pyrimidine derivatives used in diseases linked to mTOR kinase and/or PI3K |
-
2008
- 2008-07-08 KR KR1020107002969A patent/KR20100031639A/ko not_active Withdrawn
- 2008-07-08 JP JP2010515600A patent/JP2010533158A/ja active Pending
- 2008-07-08 EP EP08776181A patent/EP2074118A2/en not_active Withdrawn
- 2008-07-08 AR ARP080102944A patent/AR067478A1/es unknown
- 2008-07-08 CA CA 2692945 patent/CA2692945A1/en not_active Abandoned
- 2008-07-08 WO PCT/GB2008/050546 patent/WO2009007748A2/en not_active Ceased
- 2008-07-08 BR BRPI0814818A patent/BRPI0814818A2/pt not_active IP Right Cessation
- 2008-07-08 CN CN200880106248A patent/CN101801962A/zh active Pending
- 2008-07-08 AU AU2008273889A patent/AU2008273889B2/en not_active Expired - Fee Related
- 2008-07-08 EA EA201000092A patent/EA201000092A1/ru unknown
- 2008-07-09 PE PE2008001149A patent/PE20090773A1/es not_active Application Discontinuation
- 2008-07-09 TW TW097125962A patent/TW200904813A/zh unknown
- 2008-07-09 US US12/170,128 patent/US20090018134A1/en not_active Abandoned
- 2008-07-09 CL CL2008002006A patent/CL2008002006A1/es unknown
- 2008-07-09 UY UY31215A patent/UY31215A1/es unknown
-
2010
- 2010-01-06 ZA ZA2010/00106A patent/ZA201000106B/en unknown
- 2010-01-08 CR CR11201A patent/CR11201A/es not_active Application Discontinuation
- 2010-01-08 DO DO2010000011A patent/DOP2010000011A/es unknown
- 2010-01-08 NI NI201000004A patent/NI201000004A/es unknown
- 2010-02-09 CO CO10014104A patent/CO6390066A2/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010533158A5 (cg-RX-API-DMAC10.html) | ||
| JP2017538750A5 (cg-RX-API-DMAC10.html) | ||
| RU2017125520A (ru) | Соединения, ингибирующие parg | |
| RU2017124425A (ru) | Производные 2,4-диоксо-хиназолин-6-сульфонамида в качестве ингибиторов parg | |
| JP2019516737A5 (cg-RX-API-DMAC10.html) | ||
| RU2019132212A (ru) | Селективные ингибиторы hdac6 | |
| RU2021127810A (ru) | Замещенные гетероарилом пиридины и способы применения | |
| JP2020516671A5 (cg-RX-API-DMAC10.html) | ||
| JP2018535999A5 (cg-RX-API-DMAC10.html) | ||
| JP2007530690A5 (cg-RX-API-DMAC10.html) | ||
| JP2015517580A5 (cg-RX-API-DMAC10.html) | ||
| JP2007523142A5 (cg-RX-API-DMAC10.html) | ||
| EA020460B1 (ru) | Производные сульфонамида | |
| RU2018145045A (ru) | Соединения бензолсульфонамида и их применение в качестве терапевтических средств | |
| RU2013143028A (ru) | Тиазолилфенилбензолсульфонамидопроизводные в качестве ингибиторов киназ | |
| JP2019537571A5 (cg-RX-API-DMAC10.html) | ||
| RU2004121029A (ru) | Производные пиримидина в качестве модуляторов рецептора инсулинподобного фактора роста 1 (igf-1) | |
| CA2557115A1 (en) | Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine d3 receptors | |
| RU2016133626A (ru) | 2-амино-3,5,5-трифтор-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1 для лечения болезни альцгеймера | |
| JP2009536196A5 (cg-RX-API-DMAC10.html) | ||
| JP2013533868A5 (cg-RX-API-DMAC10.html) | ||
| CA2554310A1 (en) | Benzamide derivatives and their use as glucokinase activating agents | |
| JP2007523208A5 (cg-RX-API-DMAC10.html) | ||
| JP2017506237A5 (cg-RX-API-DMAC10.html) | ||
| RU2016141646A (ru) | Ингибиторы trka киназы, основанные на них композиции и способы |